1. What Is TB-500
TB-500 is a synthetic peptide derived from Thymosin Beta-4, a naturally occurring protein found in virtually all mammalian cells. Thymosin Beta-4 was first isolated from calf thymus tissue and is one of the most abundant intracellular proteins, with concentrations reaching as high as 0.5 mM inside cells.
The peptide gained initial attention in equine medicine, where it was used to support recovery from tendon injuries in racehorses. It subsequently became widely discussed in the research peptide community for its potential tissue repair and anti-inflammatory properties.
2. TB-500 vs Thymosin Beta-4: The Naming Problem
This is important to understand before evaluating any TB-500 product or its research literature:
Thymosin Beta-4 (full-length)
43 amino acids, ~4,963 Da. This is the complete, naturally occurring peptide. The vast majority of published scientific research was conducted on this full-length version.
TB-500 Fragment (LKKTETQ)
7 amino acids, ~889 Da in the acetylated form typically sold (~847 Da unmodified). This is the active actin-binding motif from amino acids 17–23 of Thymosin Beta-4. Some sources define “TB-500” as specifically this fragment.
In the commercial peptide market, most products labeled “TB-500” contain the full 43-amino-acid Thymosin Beta-4 sequence, not the 7-amino-acid fragment. This matters for lab testing: the molecular weight on a COA should tell you which version you actually have. If the mass spec shows ~4,963 Da, it's the full-length peptide. If it shows ~889 Da, it's the fragment.
It also matters when reading research papers. A study on “Thymosin Beta-4” used the full-length peptide. Assuming those results transfer to a 7-amino-acid fragment — or vice versa — is a leap the data does not support without specific comparative studies.
3. Mechanism of Action
Thymosin Beta-4 is the major G-actin sequestering molecule in eukaryotic cells. Its primary biological function is regulating actin polymerization — the process by which individual actin proteins assemble into filaments that form the cell's structural framework.
Actin Regulation and Cell Migration
By binding monomeric G-actin and preventing premature polymerization into filaments, Thymosin Beta-4 maintains a pool of available actin monomers that can be rapidly mobilized when cells need to migrate — such as during wound healing. This is the foundation of its tissue repair effects.
Anti-Inflammatory and Anti-Fibrotic Effects
The N-terminal tetrapeptide Ac-SDKP (amino acids 1–4 of Thymosin Beta-4) has demonstrated anti-inflammatory and anti-fibrotic activity in published research. This fragment is released naturally when Thymosin Beta-4 is cleaved by enzymes in the body.
Angiogenesis
The LKKTETQ region (amino acids 17–23) has been shown to promote new blood vessel formation in wound healing models. Like BPC-157 and GHK-Cu, angiogenesis promotion is beneficial for repair but carries theoretical concerns regarding tumor vascularization.
Tissue Remodeling via SPARC
The GHK sequence found in the SPARC protein — which is abundant in tissues undergoing rapid remodeling — releases GHK peptides after injury. Thymosin Beta-4 participates in similar tissue remodeling cascades, and the two peptides are frequently studied in combination (see our GHK-Cu guide).
4. Research Evidence
5. What the Research Does Not Show
- Most published research used full-length Thymosin Beta-4, not the fragment sold as TB-500. Assuming the 43-amino-acid peptide's results apply to a 7-amino-acid fragment requires evidence that does not broadly exist. Check your product's mass spec to know which version you have.
- Human clinical trial data is limited. While Thymosin Beta-4 has been explored in clinical contexts (particularly ophthalmology), large-scale randomized controlled trials for the applications most commonly discussed (tendon repair, muscle recovery) are not available.
- Long-term safety data does not exist. The effects of repeated Thymosin Beta-4 administration over extended periods have not been characterized in human studies.
- Angiogenesis promotion carries theoretical risk. As with BPC-157 and GHK-Cu, the blood vessel formation that aids repair is a concern in the context of existing tumors or undiagnosed cancers.
- TB-500 / Thymosin Beta-4 is not FDA-approved for any medical use. It is sold as a research compound.
6. Purity and Lab Testing
HPLC Purity
Research-grade TB-500 / Thymosin Beta-4 typically tests at 98% or above. Because the full-length peptide is 43 amino acids, it is more challenging to synthesize at high purity than shorter peptides like GHK-Cu (3 amino acids) or BPC-157 (15 amino acids).
Mass Spectrometry — Critical for This Compound
Mass spec is particularly important for TB-500 because of the naming confusion. The molecular weight tells you exactly which version you have:
- ~4,963 Da = full-length Thymosin Beta-4 (43 amino acids)
- ~889 Da = acetylated LKKTETQ fragment (7 amino acids)
If the mass spec result doesn't match either of these, the product may not be what it claims.
Storage
Store lyophilized TB-500 at -20°C, protected from light and moisture. After reconstitution, refrigerate at 2–8°C.
For a complete guide to evaluating COAs, see How to Read a Peptide COA.
Summary
TB-500 is a synthetic peptide based on Thymosin Beta-4, with published research primarily in wound healing, cardiac repair, and anti-fibrotic applications. The most critical thing to understand is the naming confusion: most commercial “TB-500” is the full 43-amino-acid Thymosin Beta-4 (~4,963 Da), while some sources define TB-500 as only the 7-amino-acid LKKTETQ fragment (~889 Da acetylated). Mass spectrometry is the definitive way to determine which version a product contains.